Vepugratinib

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Carcinoma, Transitional CellNeoplasm MetastasisUrinary Bladder Neoplasms

Phase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

RecruitingNCT07218380

Eli Lilly and CompanyCarcinoma, Transitional Cell, Neoplasm Metastasis, Urinary Bladder Neoplasms

Start: 2025-12-12End: 2033-05-01Target: 450Updated: 2026-07-13

Unknown Phase

Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Eli Lilly and CompanyCarcinoma, Transitional Cell, Neoplasm Metastasis, Urinary Bladder Neoplasms

Updated: 2026-06-30